The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.
White Paper
IND Ready Is Not Phase 2 Ready
Related Resources
All Resources
post
Regulatory Medical Writing: What Is It and What Do They Do?
Read More
post
CMC Safety and Efficacy in Gene and Cell Therapies
Read More
post
Accelerating Drug Development: Regulatory Strategies for Fast-Track and Breakthrough Therapy Designations
Read More
post
Navigating the Evolution from ICH Q2(R1) to ICH Q2(R2) and Implementation of ICH Q14 in Biopharmaceutical Method Validation
Read More
Let's move from science to success.
Let’s Talk